Articles written by professionals from The Wellington Hospital for Healthcare Professionals.
In March this year, GeneHealth UK began holding regular clinics at the Platinum Medical Centre.
Sessions are run by genetic counsellor, Vicki Kiesel, who offers private genetic tests for a range of cancers, including breast, prostate, bowel and ovarian. Although cancer is not often inherited, in some families there may be an increased risk due to a genetic mutation.
GeneHealth UK is the leading provider of early detection services and offers clinical diagnostics designed to detect cancer at an early stage, increasing the opportunity for successful treatment. Genetic testing can help determine the risk of cancer within a family and guide appropriate cancer screening for that patient. Specific screening tests are administered depending on the genetic risk of the individual, with risk reducing strategies also considered.
Historically, the remit of genetic testing has been to assess the risk of future cancers. But through the use of Sanger sequencing single genes, this has taken months, even years, to analyse. With the advent of Next-Generation Sequencing, multiple genes can now be simultaneously analysed, providing results within weeks and allowing testing at the point of diagnosis. This has meant that genetic testing is now becoming incorporated into the treatment pathway of cancer patients, guiding their current cancer management and future risk reduction options.
BreastGene is part of the GeneHealth UK service, and looks at 10 specific genes which cause an increased risk of breast cancer, particularly breast and ovarian cancers, including BRCA1 and BRCA2.
For women who’ve been diagnosed with breast cancer the identification of a BRCA mutation makes a big difference. Instead of a wide local excision followed by radiotherapy, women with BRCA mutations may opt to have a bilateral mastectomy, particularly because studies have now shown this results in a clear survival benefit. It is also important that women with BRCA1-associated triple negative breast cancer have chemotherapy regardless of stage, as this has also been shown to create a survival benefit. All women with BRCA mutations should consider a bilateral salphingo-ophorectomy once they’ve completed their families and are aged 40+.
Once a BRCA mutation has been identified it is then possible to offer predictive testing to relatives, with first degree relatives having a 50% chance of also carrying the mutation. Unaffected women can then be offered increased breast cancer surveillance, chemoprevention and risk reducing surgery.
For further information about genetic testing, please head to www.GeneHealthUK.com
GeneHealth UK, BRCA, Genetic Screening, BRCA1, BRCA2, mutation, Genetics, Vickie Kiesel, Breast, Prostate, Bowel, Ovarian, Cancer, inherited,Genetic testing, Sanger, Sequencing
|Coronary Disease: A new era in percutaneous treatment|
|Explore This Issue|
|Explore Other Issues|
|Web Exclusive Content:|
|No, this article has the same content as on our printed version|
|To download this article click here and select PDF as the printer.|
© Copyright 2018 - Practice Matters Magazine